8-K: GRI Bio Implements 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance

GRI Bio has enacted a 1-for-7 reverse stock split to increase its share price and meet Nasdaq's minimum bid price requirement.

Summary

• GRI Bio, Inc. has completed a 1-for-7 reverse stock split of its common stock.
• The reverse stock split became effective on January 29, 2024, at 4:01 p.m. Eastern Time.
• Trading on a post-split basis commenced on January 30, 2024.
• Every seven shares of common stock were converted into one share.
• The reverse stock split reduced the number of outstanding shares from approximately 4,520,233 to approximately 645,736.
• The total number of authorized shares remains unchanged at 260,000,000.
• Fractional shares resulting from the split will be paid out in cash based on the closing price on January 29, 2024.
• The company's stock will continue to trade under the ticker symbol 'GRI' with a new CUSIP number 3622AW 205.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the reverse stock split is a necessary step to maintain Nasdaq listing, it also indicates underlying issues with the company's stock price. The company's future success depends on its ability to develop and commercialize its product candidates.

Positives

• The reverse stock split is intended to increase the per share trading price of the company's common stock.
• The company aims to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Negatives

• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
• The company was required to take this action to avoid delisting from the Nasdaq Capital Market.

Risks

• The company may not be able to maintain the listing of its common stock on Nasdaq.
• There is a risk that the company may not be able to raise financing in the future.
• The company faces risks related to the success, cost, and timing of its product development activities.
• The company may not be able to obtain regulatory clearance or approval for its products.
• The company may not be able to compete with other companies in the market.

Future Outlook

The company intends to regain compliance with the Nasdaq minimum bid price requirement through the reverse stock split. The company continues to develop its pipeline of NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.

Management Comments

• The board of directors of the Company approved a 1-for-7 reverse stock split of the Company's common stock.
• The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. This action is often taken by companies in the biotechnology sector, which can experience significant volatility in their stock prices due to the nature of their research and development activities.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges have implemented reverse stock splits to maintain their Nasdaq listing.
• For example, companies like Agenus Inc. and VBI Vaccines Inc. have also recently undertaken reverse stock splits to meet Nasdaq's minimum bid price requirements.
• The 1-for-7 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more depending on the specific circumstances of the company.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on Nasdaq.
• Employees may be impacted by the company's financial performance and stock price.

Next Steps

• The company will continue to trade on The Nasdaq Capital Market under the symbol 'GRI'.
• The company will focus on its pipeline of NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.

Key Dates

Keywords

reverse stock split, Nasdaq, common stock, GRI Bio, minimum bid price, stock split, biotechnology, listing compliance